Information Provided By:
Fly News Breaks for January 8, 2020
Jan 8, 2020 | 06:34 EDT
JMP Securities analyst Jason Butler reiterated an Outperform rating and $79 price target on Arena Pharmaceuticals after the company provided an update on its corporate outlook for 2020 and beyond, with the highlights being plans for eight Phase 2 and 3 readouts by year-end 2021 and at least one new IND each year through 2024. In a research note to investors, Butler says he believes the company remains well funded and has the right management team in place to execute on the expanding opportunity set.
News For ARNA From the Last 2 Days
There are no results for your query ARNA